STOCK TITAN
  1. Home
  2. Sec-filings
  3. SNTI
  4. [8-K] Senti Biosciences, Inc. Reports Material Event

[8-K] Senti Biosciences, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock SNTI logo
Senti Bioscience

NASDAQ:SNTI

SNTI Rankings

#5338 Ranked by Market Cap
N/A Ranked by Dividends

SNTI Latest News

Aug 12, 2025
Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing The Phase 2 Dose and Schedule Selection for SENTI-202 in its Clinical Trial for Acute Myeloid Leukemia
Aug 7, 2025
Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025
Aug 5, 2025
Senti Bio Determines Recommended Phase 2 Dose (RP2D) in Phase 1 Study of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies, Including Acute Myeloid Leukemia
Jul 22, 2025
Senti Biosciences Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference
Jul 21, 2025
Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum

SNTI Latest SEC Filings

Aug 7, 2025
[10-Q] Senti Biosciences, Inc. Quarterly Earnings Report
Aug 7, 2025
[8-K] Senti Biosciences, Inc. Reports Material Event
Jul 21, 2025
[Form 4] Senti Biosciences, Inc. Insider Trading Activity
Jul 21, 2025
[Form 3] Senti Biosciences, Inc. Initial Statement of Beneficial Ownership
Jun 30, 2025
[8-K] Senti Biosciences, Inc. Reports Material Event

SNTI Stock Data

41.21M
11.24M
57.21%
28.21%
2.51%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SOUTH SAN FRANCISCO